Analysts forecast that Regeneron Pharmaceuticals Inc (NASDAQ:REGN) will announce earnings per share of $5.49 for the current quarter, Zacks Investment Research reports. Seven analysts have issued estimates for Regeneron Pharmaceuticals’ earnings. The highest EPS estimate is $6.15 and the lowest is $5.08. Regeneron Pharmaceuticals posted earnings of $4.67 per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 17.6%. The firm is expected to report its next quarterly earnings report before the market opens on Tuesday, May 7th.

On average, analysts expect that Regeneron Pharmaceuticals will report full year earnings of $23.37 per share for the current fiscal year, with EPS estimates ranging from $20.18 to $25.34. For the next fiscal year, analysts anticipate that the company will post earnings of $26.52 per share, with EPS estimates ranging from $23.81 to $29.89. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that cover Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Wednesday, February 6th. The biopharmaceutical company reported $6.84 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $5.10 by $1.74. Regeneron Pharmaceuticals had a return on equity of 29.77% and a net margin of 36.43%. The business had revenue of $1.93 billion during the quarter, compared to analysts’ expectations of $1.73 billion. During the same quarter in the prior year, the business earned $5.23 earnings per share. The company’s quarterly revenue was up 21.9% compared to the same quarter last year.

Several equities research analysts have recently commented on the company. Zacks Investment Research cut Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, February 8th. BidaskClub downgraded Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, March 16th. BMO Capital Markets boosted their price objective on Regeneron Pharmaceuticals to $412.00 and gave the stock a “market perform” rating in a research note on Thursday, February 7th. Guggenheim downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $466.00 to $425.00 in a research note on Friday, February 22nd. Finally, Jefferies Financial Group dropped their price objective on Regeneron Pharmaceuticals from $376.00 to $343.00 and set a “hold” rating on the stock in a research note on Wednesday, April 17th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $413.94.

Shares of Regeneron Pharmaceuticals stock traded up $6.97 during trading hours on Thursday, hitting $341.00. 13,710 shares of the company were exchanged, compared to its average volume of 747,474. Regeneron Pharmaceuticals has a 1 year low of $281.89 and a 1 year high of $442.00. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.47 and a quick ratio of 3.67. The stock has a market capitalization of $37.15 billion, a PE ratio of 17.25, a price-to-earnings-growth ratio of 1.29 and a beta of 1.18.

In related news, major shareholder Sanofi sold 131,115 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, March 8th. The stock was sold at an average price of $412.17, for a total value of $54,041,669.55. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 12.42% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in REGN. Whittier Trust Co. boosted its position in Regeneron Pharmaceuticals by 195.7% during the fourth quarter. Whittier Trust Co. now owns 68 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 45 shares during the last quarter. Rehmann Capital Advisory Group boosted its position in Regeneron Pharmaceuticals by 1,700.0% during the third quarter. Rehmann Capital Advisory Group now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 68 shares during the last quarter. AdvisorNet Financial Inc boosted its position in Regeneron Pharmaceuticals by 208.0% during the fourth quarter. AdvisorNet Financial Inc now owns 77 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 52 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in Regeneron Pharmaceuticals during the first quarter valued at $29,000. Finally, Captrust Financial Advisors acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at $30,000. 66.97% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Read More: Market Capitalization

Get a free copy of the Zacks research report on Regeneron Pharmaceuticals (REGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.